Ilyang Pharmaceutical’s Supect shows high generic response than Glivec
A phase III clinical trial result of ‘Supect(radotinib),’ the Asia’s first leukemia treatment developed by Ilyang Pharmaceutical, was published an online-version of an international journal ‘Clinical Cancer Research,’ on the 22nd of September. The medical journal published a treatment result of f...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
